Inmedic Group ApS: Financial statements 2022
CVR: 40711171
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Inmedic Group ApS (CVR 40711171) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 514,472 and a net result of DKK 433,331 compared with DKK -166,144 the year before. Equity in the 2022 report amounted to DKK 761,717. The solvency ratio was 83.5%.
- Gross Profit
- DKK 514,472
- Profit/Loss
- DKK 433,331
- Equity
- DKK 761,717
- Total Assets
- DKK 912,387
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 514 t. | 433 t. | 762 t. | 0 |
| 2021 | - | -156 t. | -166 t. | 328 t. | 0 |
Official annual report
Keep an eye on Inmedic Group ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Inmedic Group ApS has published its annual report for 2021. Gross profit came to DKK -156,219, and the net result was DKK -166,144.
About Inmedic Group ApS
Inmedic Group ApS is a Danish company of the type Anpartsselskab based in Vejle, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named Nordic Cannabis Research ApS. The management consists of Henrik Lund Uth. The company is owned by DAM-ANDERSEN ApS, HEMAR ApS and Schejbel Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 102,384 and a net result of DKK 563,568 compared with DKK 441,754 the year before. Equity in the 2025 report amounted to DKK 2,131,008.